Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protselan is a multi-component topical ointment developed by the Research Institute for Physical Chemical Problems of the Belarusian State University. It is specifically formulated for the treatment of infected wounds, burns, and various dermatological conditions that require a combination of antimicrobial action, local anesthesia, and tissue regeneration. The drug's formulation typically includes dioxidine (a broad-spectrum quinoxaline-derivative antibacterial agent), trimecaine (a local anesthetic), and methyluracil (a pyrimidine derivative that stimulates cellular repair). Protselan is particularly effective during the first phase of the wound healing process, where it provides bactericidal activity against aerobic and anaerobic microorganisms, reduces inflammatory edema, and alleviates local pain while preparing the wound bed for granulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Protselan.